GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Shareholder Yield %

Zai Lab (Zai Lab) Shareholder Yield % : -0.40% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zai Lab Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Zai Lab's Shareholder Yield % was -0.40%.


Zai Lab Shareholder Yield % Historical Data

The historical data trend for Zai Lab's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Shareholder Yield % Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only -5.79 -3.76 0.03 -0.09 0.07

Zai Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.10 -0.02 0.07 -0.53

Competitive Comparison of Zai Lab's Shareholder Yield %

For the Biotechnology subindustry, Zai Lab's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Zai Lab's Shareholder Yield % falls into.



Zai Lab Shareholder Yield % Calculation

Zai Lab's Shareholder Yield % for the quarter that ended in Mar. 2024 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0 %+-0.53 %
=-0.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Zai Lab  (NAS:ZLAB) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Zai Lab Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Zai Lab's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab (Zai Lab) Business Description

Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Harald Reinhart officer: Chief Medical Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Edmondson Frazor Titus Iii officer: Chief Legal Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Ying Du director, officer: Chairwoman & CEO C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Rafael Amado officer: See Remarks 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Joshua L Smiley officer: Chief Operating Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen officer: Chief Financial Officer 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth director 37 HANCOCK STREET, BOSTON MA 02114
John D Diekman director C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Tao Fu director, officer: President & COO 3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul officer: Chief Financial Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen director 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210